Deuruxolitinib Phosphate

Sun Pharma has agreed to pay $11.75 billion for Organon in a merger of companies that each generated sales of $6.2 billion last year. It is the largest deal ever struck by an Indian biopharma company, Sun said. Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) of women’s health leader Organon. With its $11.75 billion buyout, Sun has picked up a drugmaker that matched the $6.2 billion in sales that it generated in 2025.Sun is paying $14 per share, which is a 24% premium on Organon’s closing price on Friday. It is also a more than 100% premium on Organon’s share price at the start of April. With the agreement, which is expected to close by early 2027, Sun’s stock increased by 7%, while Organon’s jumped by 17%.The deal, which is the largest ever by an Indian biopharma, the company said, will boost Sun’s portfolio of innovative medicines and will catapult it to No. 7 among the world’s top sellers of biosimilars, the company said in its release. While Indian companies are exempt from paying tariffs on the generic products they export to the United States, Sun’s U.S. sales have declined recently, prompting it to boost its presence in branded products and biosimilars.Organon’s stock had been weighed down by “heavy headwinds,” according to Evercore ISI analyst Umer Raffat, citing the New Jersey company’s debt, its oncoming loss of exclusivity of contraceptive implant Nexplanon and its “bad M&A to digest,” which is a reference to Organon’s $1.2 billion 2024 buyout of Dermavant. The acquisition brought non-steroid skin cream Vtama, which achieved sales of $128 million in 2025, coming up short of the $150 million target the company set at the start of the year.  Since it was spun out of Merck in 2021, Organon’s sales have been stagnant, toggling between $6.2 billion and $6.4 billion for each of the last four years.The company, however, brings “excellent people from Merck” and an “excellent set of legacy Merck brands,” Raffat wrote in his note to clients. The deal is the largest in the industry so far this year, topping Eli Lilly’s recent buyouts of Centessa Pharmaceuticals and Kelonia Therapeutics, which were for headline values of $7.8 billion and $7 billion, respectively. Also, within the last five weeks as biopharma M&A activity has heated up, Merck put up $6.7 billion to acquire Terns Pharmaceuticals, Biogen picked up Apellis for $5.6 billion and Gilead purchased Tubulis for a headline value of $5 billion.Mostly known as a seller of generics, Sun has built a specialty business in dermatology, ophthalmology and oncology-dermatology in recent years, thanks in part to acquisitions of Concert Pharmaceuticals, for $576 million in 2023, to gain a JAK inhibitor treatment for alopecia, Leqselvi, and Checkpoint Therapeutics, for $418 million last year, to gain cancer immunotherapy Unloxcyt. Organon traces its roots to 1923 in The Netherlands. Schering-Plough acquired the company in 2007, two years before it merged with Merck. Today, the company sells (PDF) more than 70 medicines in roughly 140 countries and manufactures its products at six sites in Europe.“This transaction is a logical next step in strengthening Sun Pharma’s global business,” Kirti Ganorkar, Sun’s managing director, said in a release. “Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration and responsible value creation. We see strong potential in leveraging Organon’s talent pool.”